General Info

Rather than aiming to only symptomatically treat cardiovascular disease, the discoveries of Dimera Incorporated that shape the company s research and development offerings are based on growing insights into balancing genomic regulatory contributions. Many of the company s primary discoveries are focused on blood-vessel reactivity, in particular the abnormal increase in coronary artery contraction, also known as vasoconstriction, that occurs in heart disease, which severely limits an individual s ability to exercise. Dimera Incorporated s strategies develop from recognition that failure of coronary artery reactivity modulation contributes to coronary artery disease, along with atherosclerosis.